BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22257303)

  • 21. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 22. Guillain-Barré syndrome after treatment with sunitinib malate?
    Mulherin B; Loconte NK; Holen KD
    Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
    J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
    [No Abstract]   [Full Text] [Related]  

  • 25. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
    Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
    JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
    [No Abstract]   [Full Text] [Related]  

  • 26. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
    van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
    Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
    [No Abstract]   [Full Text] [Related]  

  • 27. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
    Flaig TW; Kim FJ; La Rosa FG; Breaker K; Schoen J; Russ PD
    Invest New Drugs; 2009 Feb; 27(1):83-7. PubMed ID: 18563296
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
    Rolleman EJ; Weening J; Betjes MG
    Nephrol Dial Transplant; 2009 Jun; 24(6):2002-3. PubMed ID: 19332867
    [No Abstract]   [Full Text] [Related]  

  • 29. Sunitinib-induced acute hemolysis without hypertension: a case report.
    Jain R; Mathew P; Wood CG; Tannir NM
    Clin Genitourin Cancer; 2008 Sep; 6(2):122-3. PubMed ID: 18824436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 31. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
    Lankheet NA; Blank CU; Mallo H; Adriaansz S; Rosing H; Schellens JH; Huitema AD; Beijnen JH
    J Anal Toxicol; 2011 Oct; 35(8):558-65. PubMed ID: 22004675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
    Duchnowska R; Miciuk B; Bodnar L; Waśniewski L; Szczylik C
    J Oncol Pharm Pract; 2013 Jun; 19(2):186-9. PubMed ID: 23037634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib-induced thyrotoxicosis.
    Piñar D; Boix E; Meana JA; Herrero J
    J Endocrinol Invest; 2009 Dec; 32(11):941-2. PubMed ID: 19636224
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
    Togo Y; Shimatani K; Hanasaki T; Yo T; Nakanishi Y; Nagasawa S; Hashimoto T; Shiraishi Y; Taoka R; Suzuki T; Go S; Higuchi Y; Kanematsu A; Nojima M; Tsuchihashi K; Makino Y; Shimizu Y; Kanamaru S; Kono Y; Matsumoto K; Utsunomiya N; Ito N; Kawakita M; Yamamoto S
    Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
    Szmit S; Nurzyński P; Szaluś N; Opolski G; Szczylik C
    Acta Oncol; 2009; 48(6):921-5. PubMed ID: 19191048
    [No Abstract]   [Full Text] [Related]  

  • 37. Sunitinib-induced subungual splinter haemorrhage and acral erythema.
    Nakamura M; Miyachi Y
    Eur J Dermatol; 2008; 18(3):344-5. PubMed ID: 18474471
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
    Park CY
    Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensive necrotizing fasciitis associated with sunitinib therapy.
    Piszczek J; Dalton B; Peters T; Ruether D; Urbanski S
    Clin Genitourin Cancer; 2014 Apr; 12(2):e47-9. PubMed ID: 24445249
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.
    Zhou A
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):132-44. PubMed ID: 22524572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.